TY - JOUR T1 - Bazedoxifene for HRT? JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull SP - 42 LP - 44 DO - 10.1136/dtb.2017.4.0466 VL - 55 IS - 4 A2 - , Y1 - 2017/04/01 UR - http://dtb.bmj.com/content/55/4/42.abstract N2 - Duavive (Pfizer) is a modified-release formulation of conjugated oestrogens plus bazedoxifene acetate (a selective oestrogen receptor modulator). It is licensed for treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus for whom treatment with progestogen-containing therapy is not appropriate.1,2 It was licensed by the European Medicines Agency (EMA) in 2014 and launched in the UK in July 2016.1,3 Here, we review the evidence on efficacy and safety of conjugated oestrogens/bazedoxifene and consider its place in the management of symptoms associated with the menopause. ER -